The Hepatitis A Vaccine is a vaccine used to protect against the Hepatitis A virus. It is given as an injection into the arm muscle, usually in two doses six months apart. The first dose provides protection for up to 12 months and the second dose provides long-term protection.
Hepatitis A is a highly contagious liver infection caused by the Hepatitis A virus. It is spread through contact with contaminated food or water, or through close contact with an infected person. Symptoms vary from mild to severe and can include jaundice, abdominal pain, nausea, fever, and fatigue. In some cases, Hepatitis A can cause liver failure or death.
The Hepatitis A Vaccine is highly effective in preventing infection, and is recommended for all children aged 12 months and older, as well as adults at risk of infection. It is also recommended for travelers to certain countries where Hepatitis A is common.
The global Hepatitis A Vaccine market was valued at US$ 705.8 million in 2022 and is anticipated to reach US$ 840.5 million by 2029, witnessing a CAGR of 2.2% during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
A detailed market research report on Global Hepatitis A Vaccine Market available at: https://www.themarketreports.com/report/global-hepatitis-a-vaccine-market-research-report
This report aims to provide a comprehensive presentation of the global market for Hepatitis A Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatitis A Vaccine.
Global hepatitis a vaccine key players include GSK, Merck, Sanofi, etc. Global top 5 manufacturers hold a share over 80%.
Ask for more details or sample of this report at: https://www.themarketreports.com/report/ask-your-query/1411305
The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479